Product Number |
ARP38941_T100 |
Product Page |
www.avivasysbio.com/tardbp-antibody-n-terminal-region-arp38941-t100.html |
Name |
TARDBP Antibody - N-terminal region (ARP38941_T100) |
Protein Size (# AA) |
414 amino acids |
Molecular Weight |
45kDa |
NCBI Gene Id |
23435 |
Host |
Rabbit |
Clonality |
Polyclonal |
Concentration |
1.0 mg/ml |
Gene Full Name |
TAR DNA binding protein |
Description |
|
Alias Symbols |
ALS10, TDP-43 |
Peptide Sequence |
Synthetic peptide located within the following region: MSEYIRVTEDENDEPIEIPSEDDGTVLLSTVTAQFPGACGLRYRNPVSQC |
Product Format |
Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
Reference |
Buratti,E., (2005) J. Biol. Chem. 280 (45), 37572-37584 |
Description of Target |
HIV-1, the causative agent of acquired immunodeficiency syndrome (AIDS), contains an RNA genome that produces a chromosomally integrated DNA during the replicative cycle. Activation of HIV-1 gene expression by the transactivator Tat is dependent on an RNA regulatory element (TAR) located downstream of the transcription initiation site. TARDBP is a transcriptional repressor that binds to chromosomally integrated TAR DNA and represses HIV-1 transcription.HIV-1, the causative agent of acquired immunodeficiency syndrome (AIDS), contains an RNA genome that produces a chromosomally integrated DNA during the replicative cycle. Activation of HIV-1 gene expression by the transactivator Tat is dependent on an RNA regulatory element (TAR) located downstream of the transcription initiation site. The protein encoded by this gene is a transcriptional repressor that binds to chromosomally integrated TAR DNA and represses HIV-1 transcription. In addition, this protein regulates alternate splicing of the CFTR gene. A similar pseudogene is present on chromosome 20. |
Protein Interactions |
ZFAND2B; TARDBP; UBC; SUMO2; STAU1; SUMO3; RNF4; USP8; RBM45; RNF2; LSM6; UBE2E3; GNB2L1; MED6; RPA1; WWOX; RPA3; RPA2; PARK2; EED; BMI1; RBM39; BAG2; RPL23; DDX21; PRPF3; USP10; SART1; RPL14; H1FX; FUBP3; PABPC4; EIF4G3; EIF3I; EIF3H; EIF3C; EIF3B; EIF3A |
Reconstitution and Storage |
For short term use, store at 2-8C up to 1 week. For long term storage, store at -20C in small aliquots to prevent freeze-thaw cycles. |
Enhanced Validation |
Relative Expression (Western Blot) |
|
|
Datasheets/Manuals |
Printable datasheet for anti-TARDBP (ARP38941_T100) antibody |
Blocking Peptide |
For anti-TARDBP (ARP38941_T100) antibody is Catalog # AAP38941 (Previous Catalog # AAPY00750) |
Immunogen |
The immunogen is a synthetic peptide directed towards the N terminal region of human TARDBP |
Uniprot ID |
Q13148 |
Protein Name |
TAR DNA-binding protein 43 |
Publications |
Estes, P. S. et al. Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS. Hum. Mol. Genet. 20, 2308-21 (2011). 21441568 |
Sample Type Confirmation |
TARDBP is supported by BioGPS gene expression data to be expressed in HepG2 |
Protein Accession # |
NP_031401 |
Purification |
Protein A purified |
Nucleotide Accession # |
NM_007375 |
Tested Species Reactivity |
Human |
Gene Symbol |
TARDBP |
Predicted Species Reactivity |
Human, Mouse, Rat, Cow, Dog, Guinea Pig, Horse |
Application |
IHC, WB |
Predicted Homology Based on Immunogen Sequence |
Cow: 100%; Dog: 100%; Guinea Pig: 100%; Horse: 100%; Human: 100%; Mouse: 100%; Rat: 100% |
Image 1 | HepG2
| Host: Rabbit Target Name: TARDBP Sample Type: HepG2 Lane A: Primary Antibody Lane B: Primary Antibody + Blocking Peptide Primary Antibody Concentration: 1.25ug/mL Peptide Concentration: 1.0ug/mL Lysate Quantity: 25ug/lane Gel Concentration: 12%TARDBP is supported by BioGPS gene expression data to be expressed in HepG2 |
|
Image 2 | Human Liver
| Human Liver |
|
Image 3 | Human kidney
| Human kidney |
|
Image 4 | Western Blot
| 25 ug of the indicated whole cell extracts was loaded onto a 12% SDS-PAGE gel. 5 ug/mL of the antibody was used in this experiment. Recommended dilution for antibody is 1-3 ug/mL. Two or more isoforms of this protein are known and at least two share the N-terminal peptide sequence. |
|